ADT Associated With Alzheimer Disease, Dementia in Prostate Cancer Survivors

Rachel Narozniak
Published: Tuesday, Aug 06, 2019
Androgen deprivation therapy (ADT) increases the risk of subsequent Alzheimer disease and dementia among men ≥66 years with prostate cancer (PC), according to findings of a large retrospective study (N = 154,089) that examined the link between ADT treatment and later cognitive dysfunction.1 Investigators said patients with PC who received ADT were more likely to receive a diagnosis of Alzheimer disease or dementia than those not treated with ADT.

The retrospective cohort study was the largest analysis to date of the association between ADT exposure and subsequent dementia in a population of elderly US men with prostate cancer, according to investigators.

References

  1. Jayadevappa R, Chhatre S, Malkowicz SB, Parikh RB, Guzzo T, Wein AJ. Association between androgen deprivation therapy use and diagnosis of dementia in men with prostate cancer. JAMA Netw Open. 2019;2(7):e196562. doi: 10.1001/jamanetworkopen.2019.6562.
  2. Kandola A. What is the difference between dementia and Alzheimer’s? Medical News Today website.medicalnewstoday.com/articles/ 323283.php. Updated October 9, 2018. Accessed July 16, 2019.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 3rd Annual International Congress on Oncology & Pathology™Aug 30, 20201.5
Community Practice Connections™: ASCO Direct™ Highlights – 2019 Official Annual Meeting ReviewAug 30, 20201.5
Publication Bottom Border
Border Publication
x